Question to the Department of Health and Social Care:

To ask His Majesty's Government why they are yet to add any products to the Innovative Medicines Fund.

The National Institute for Health and Care Excellence (NICE) makes recommendations for any suitable medicine for inclusion in the Innovative Medicines Fund (IMF). The IMF is a managed access fund, which provides a route for earlier patient access for the most promising new medicines while further evidence is collected to inform a long-term commissioning recommendation.

NICE’s independent committee may consider managed access, if a recommendation for routine commissioning cannot be made and where collection of further evidence during a period of managed access will sufficiently support the case for such a recommendation in the future. To date, NICE has not recommended any medicines into the IMF. NICE and NHS England continually monitor for potential products for inclusion in the IMF and NICE provides guidance on whether a managed access proposal would be feasible.